Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPRC5D HHE program
- Development stage
- Preclinical
- Lead developer
- Abilita Therapeutics
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Abilita Therapeutics' GPRC5D HHE program is an early-stage therapeutic candidate targeting G protein-coupled receptor class C group 5 member D (GPRC5D) for the treatment of multiple myeloma. Developed using Abilita's proprietary Enhanced Membrane Protein (EMP) platform, which stabilizes complex transmembrane proteins like GPCRs in their native conformation to facilitate drug discovery, the program focuses on generating high-affinity humanized heavy-chain-only antibodies (HHE). GPRC5D is a highly specific surface antigen expressed on malignant plasma cells, making it a validated target for multiple myeloma therapies. The HHE modality is designed to offer advantages such as high specificity, potential for better tissue penetration, and the ability to bind to challenging epitopes on the GPCR target. The program is currently in the discovery and lead optimization stages.
- Other names
- Abilita Therapeutics GPRC5D HHE
02
Targets
GPRC5D
Beyond the preview
Go deeper on GPRC5D HHE program.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPRC5D HHE program.